Diffuse large B cell lymphoma (DLBCL), the most common lymphoid malignancy in adults, is
a clinically and genetically heterogeneous disease that is further classified into …

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin
lymphoma. Although 5-year survival rates in the first-line setting range from 60% to 70%, up …

To gain insight into the genomic basis of diffuse large B-cell lymphoma (DLBCL), we
performed massively parallel whole-exome sequencing of 55 primary tumor samples from …

Purpose Twenty percent of patients with follicular lymphoma (FL) experience progression of
disease (POD) within 2 years of initial chemoimmunotherapy. We analyzed data from the …

PURPOSE: This phase II trial investigated the safety and efficacy of re-treatment with
rituximab, a chimeric anti-CD20 monoclonal antibody, in patients with low-grade or follicular …

Purpose To determine whether a response classification based on integration of fluorine-18–
fluorodeoxyglucose positron emission tomography (FDG-PET) into the International …

Follicular Lymphoma in the United States: First Report of the National LymphoCare Study -
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …

Purpose Studies of diffuse large B-cell lymphoma (DLBCL) are typically evaluated by using
a time-to-event approach with relapse, re-treatment, and death commonly used as the …

Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era:
A Report From the University of Iowa/Mayo Clinic Specialized Program of Research Excellence …

Ofatumumab is a unique monoclonal antibody that targets a distinct small loop epitope on
the CD20 molecule. Preclinical data show that ofatumumab is active against B-cell …